IL33 and atherosclerosis: Treatments that target interleukins, such as IL-27, IL-28, IL-29, IL-31, IL-32, and IL-33, have shown promise in reducing fibrosis and inflammation, two important processes linked to the development of heart disorders such as atherosclerosis and heart failure.